Anti-Xa trough levels for therapeutic LMWH treatment monitoring, a pilot study

Anti-Xa trough levels for therapeutic LMWH treatment monitoring, a pilot study - NXT level

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49087

Enrollment

Registered

2020-04-24

Start date

2020-08-08

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

VTE venous tromboembolic events en Atriumfibrillation

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult hospitalized patients receiving nadroparin in therapeutic doses for a period of *3days, written informed consent.

Exclusion criteria

Exclusion criteria: Patients on CVVH, peritoneal dialysis, or ECMO. Patients with congenital coagulation disorders.

Design outcomes

Secondary

Measure	Time frame
Anti-Xa trough and peak levels related to creatinine clearance and bodyweight presented per subgroup as mean ± standard deviation (or as median and ranges if data is not normally distributed, which will be tested in IBM SPSS).	—

Primary

Measure	Time frame
The primary study parameter consists of mean anti-Xa trough- and peak levels per subgroup, presented as mean ± standard deviation (or as median and ranges if data is not normally distributed, which will be tested in IBM SPSS).	—

Countries

Netherlands

Outcome results